Arcutis Biotherapeutics Inc.
ARQT
We are a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of highly differentiated topical and systemic treatments with significant potential to treat immune-mediated dermatological diseases and conditions.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$509M
▲ +91.3% YoY
Net Income (TTM)
$30M
▲ +88.5% YoY
Op. Margin
6.91%
▲ +62.1pp YoY
ROIC
10.53%
▲ +32.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$60M
▲ +94.4% YoY
Op. Cash Flow (TTM)
$60M
▲ +95.0% YoY
Net Debt
-$145M
Net Cash Position
Cash & Equiv.
$259M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with ARQT
Held by ETFs
ARQT is in 60 US ETFs. The largest of them, with ARQT's weight in each:
Arcutis Biotherapeutics (ARQT) in four numbers
Questions about Arcutis Biotherapeutics
Is Arcutis Biotherapeutics (ARQT) overvalued?
At $26.20, Arcutis Biotherapeutics' price is 2285% above the $1.10 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 119.09 times earnings and 55.49 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Arcutis Biotherapeutics' fair value?
Intrinsiqq's calculator puts Arcutis Biotherapeutics' fair value at $1.10 a share. It grows earnings per share 5% a year for 5 years, applies an exit P/E of 6.3, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.82. Every input can be changed on the Intrinsic Value tab.
Is Arcutis Biotherapeutics a high-quality business?
Arcutis Biotherapeutics scores 65 out of 100 on Intrinsiqq's quality score, which makes it a solid business on these measures. The score blends 7 checks computed from SEC filings. Its best check is revenue growth at 242.7%, and its weakest is share count change at 148.6%. The Quality tab shows every check against its target.
Does Arcutis Biotherapeutics (ARQT) pay a dividend?
No. Arcutis Biotherapeutics (ARQT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 9 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in ARQT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing ARQT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.